Citations

Showing 10 of 108104 citations.

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Focosi, Daniele , Burnouf, Thierry , Joyner, Michael J. , Casadevall, Arturo , Joyner, Michael J , Focosi, Daniele , Franchini, Massimo , Pirofski, Liise‐anne , Paneth, Nigel , Casadevall, Arturo

Mayo Clinic

Clinical Microbiology Reviews | March 9, 2022 | Volume: 35 | Issue: 3 | Pages: No page available

10.1128/cmr.00200-21 | PMID 35262370 Get It

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is available as soon as there are survivors. The COVID-19 pandemic represented the first large-scale opportunity to shed light on the mechanisms of action, safety, and efficacy of CP using modern evidence-based medicine approaches. Studies ranging from observational case series to randomized controlled trials (RCTs) have reported highly variable efficacy results for COVID-19 CP (CCP), resulting in uncertainty.
Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA‐CKD
Briguori, Carlo , Mathew, Roy O. , Huang, Zhen , Mavromatis, Kreton , Hickson, LaTonya J. , Lau, Wei Ling , Mathew, Anoop , Mahajan, Sandeep, Wheeler, David C. , Nolasco, Fernando , Stone, Gregg W. , Fleg, Jerome L. , Sidhu, Mandeep S. , Rockhold, Frank W. , Chertow, Glenn M. , Stone, Gregg W , Rockhold, Frank W , Hochman, Judith S , Bangalore, Sripal , Hickson, LaTonya J , Claes, Kathleen , Chen, Gang , Hochman, Judith S. , Maron, David J. , Bangalore, Sripal

Mayo Clinic

Journal of the American Heart Association | March 9, 2022 | Volume: 11 | Issue: 6 | Pages: No page available

10.1161/jaha.121.022003 | PMID 35261290 Get It

Background In participants with concomitant chronic coronary disease and advanced chronic kidney disease (CKD), the effect of treatment strategies on the timing of dialysis initiation is not well characterized. Methods and Results In ISCHEMIA‐CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches–Chronic Kidney Disease), 777 participants with advanced CKD and moderate or severe ischemia were randomized to either an initial invasive or conservative management strategy. Herein, we compare the proportion of randomized participants with non–dialysis‐requiring CKD at baseline (n=362) who initiated dialysis and compare the time to dialysis initiation between invasive versus conservative management arms. Using multivariable Cox regression analysis, we also sought to identify the effect of invasive versus conservative chronic coronary disease management strategies on dialysis initiation. At a median follow‐up of 23 months (25th–75th interquartile range, 14–32 months), dialysis was initiated in 18.9% of participants (36/190) in the invasive strategy and 16.9% of participants (29/172) in the conservative strategy (P= 0.22). The median time to dialysis initiation was 6.0 months (interquartile range, 3.0–16.0 months) in the invasive group and 18.2 months (interquartile range, 12.2–25.0 months) in the conservative group (P= 0.004), with no difference in procedural acute kidney injury rates between the groups (7.8% versus 5.4%; P =0.26). Baseline clinical factors associated with earlier dialysis initiation were lower baseline estimated glomerular filtration rate (hazard ratio [HR] associated with 5‐unit decrease, 2.08 [95% CI, 1.72–2.56]; P <0.001), diabetes (HR, 2.30 [95% CI, 1.28–4.13]; P =0.005), hypertension (HR, 7.97 [95% CI, 1.09–58.21]; P =0.041), and Hispanic ethnicity (HR, 2.34 [95% CI, 1.22–4.47]; P =0.010). Conclusions In participants with non–dialysis‐requiring CKD in ISCHEMIA‐CKD, randomization to an invasive chronic coronary disease management strategy (relative to a conservative chronic coronary disease management strategy) is associated with an accelerated time to initiation of maintenance dialysis for kidney failure. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01985360.
Renal mitochondrial injury in the pathogenesis of CKD: mtDNA and mitomiRs
Irazabal, María V. , Chade, Alejandro , Eirin, Alfonso , Eirin, Alfonso , Irazabal, Maria V

Mayo Clinic

Clinical Science | March 9, 2022 | Volume: 136 | Issue: 5 | Pages: 345-360

10.1042/cs20210512 | PMID 35260892 Get It

Abstract Chronic kidney disease (CKD) is a public health concern that affects over 200 million people worldwide and is associated with a tremendous economic burden. Therefore, deciphering the mechanisms underpinning CKD is crucial to decelerate its progression towards end-stage renal disease (ESRD). Renal tubular cells are populated with a high number of mitochondria, which produce cellular energy and modulate several important cellular processes, including generation of reactive oxygen species (ROS), calcium homeostasis, proliferation, and apoptosis. Over the past few years, increasing evidence has implicated renal mitochondrial damage in the pathogenesis of common etiologies of CKD, such as diabetes, hypertension, metabolic syndrome (MetS), chronic renal ischemia, and polycystic kidney disease (PKD). However, most compelling evidence is based on preclinical studies because renal biopsies are not routinely performed in many patients with CKD. Previous studies have shown that urinary mitochondrial DNA (mtDNA) copy numbers may serve as non-invasive biomarkers of renal mitochondrial dysfunction. Emerging data also suggest that CKD is associated with altered expression of mitochondria-related microRNAs (mitomiRs), which localize in mitochondria and regulate the expression of mtDNA and nucleus-encoded mitochondrial genes. This review summarizes relevant evidence regarding the involvement of renal mitochondrial injury and dysfunction in frequent forms of CKD. We further provide an overview of non-invasive biomarkers and potential mechanisms of renal mitochondrial damage, especially focusing on mtDNA and mitomiRs.
A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia
Stricker, John L. , Karstens, Aimee J. , Geske, Jennifer R. , Fields, Julie A. , Hassenstab, Jason , Tosakulwong, Nirubol , Wiste, Heather J. , Jack, Clifford R. , Kantarci, Kejal , Stricker, Nikki H. , Jack, Clifford R , Kantarci, Kejal , Hassenstab, Jason , Geske, Jennifer , Karstens, Aimee James , Schwarz, Christopher G. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | March 9, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/dad2.12299 | PMID 35280963 Get It

AbstractIntroductionThis study established the psychometric properties and preliminary validity of the Stricker Learning Span (SLS), a novel computer adaptive word list memory test designed for remote assessment and optimized for smartphone use.MethodsWomen enrolled in the Mayo Clinic Specialized Center of Research Excellence (SCORE) were recruited via e‐mail or phone to complete two remote cognitive testing sessions. Convergent validity was assessed through correlation with previously administered in‐person neuropsychological tests (n = 96, ages 55–79) and criterion validity through associations with magnetic resonance imaging measures of neurodegeneration sensitive to Alzheimer's disease (n = 47).ResultsSLS performance significantly correlated with the Auditory Verbal Learning Test and measures of neurodegeneration (temporal meta‐regions of interest and entorhinal cortical thickness, adjusting for age and education). Test–retest reliabilities across two sessions were 0.71–0.76 (two‐way mixed intraclass correlation coefficients).DiscussionThe SLS is a valid and reliable self‐administered memory test that shows promise for remote assessment of aging and neurodegenerative disorders.
Dysexecutive Alzheimer’s Disease with Lewy Body Disease Co-Pathology
Coburn, Ryan P , Graff‐Radford, Jonathan , Reichard, R. Ross , Ramanan, Vijay K. , Ramanan, Vijay K , Botha, Hugo , Jones, David T.

Mayo Clinic

Current Alzheimer Research | March 9, 2022 | Volume: 19 | Issue: 4 | Pages: 330-333

10.2174/1567205019666220308152219 | PMID 35260054 Get It

Background: Alzheimer’s disease can present atypically as a progressive dysexecutive syndrome (dAD), an entity that preferentially affects younger individuals and is frequently misdiagnosed, highlighting the imperative for additional research. Objective: The objective of this study is to characterize the clinical, antemortem neuroimaging, and postmortem neuropathologic features of two cases of young-onset dAD who displayed evidence of Lewy body disease (LBD) co-pathology at autopsy. Methods: Clinical histories, antemortem MRI and PET imaging, and postmortem neuropathologic data were reviewed for each patient. Case Descriptions/Results: Canonical features of dAD were observed in both cases, including progressive and predominant impairment in tasks related to working memory and cognitive flexibility, a lack of major behavioral/personality changes, and evidence of abnormal amyloid and tau deposition by antemortem amyloid and tau PET and postmortem neuropathology. Relative sparing of hippocampal involvement was observed in both individuals, in keeping with many cases of clinically atypical AD. One of the patients developed subtle parkinsonian signs as well as paranoia and irritability in the years prior to passing. In both cases, transitional (brainstem and limbic) LBD co-pathology was observed at autopsy. Discussion: Although LBD co-pathology is not uncommon in AD overall, the presence of LBD pathology in these young-onset cases of dAD (including a case with apparent symptomatic correlate) warrants further investigation for broader frequency and underlying pathophysiology. Conclusion: A better understanding of which specific young-onset AD phenotypes are associated with LBD co-pathology would have important implications for counseling, treatment, clinical trial enrollment, and knowledge on disease mechanisms.
Hearing Preservation in Observed Sporadic Vestibular Schwannoma: A Systematic Review
Khandalavala, Karl R., Saba, Elias S., Kocharyan, Armine, Daher, Ghazal S., Lohse, Christine M., Marinelli, John P., Carlson, Matthew L., Khandalavala, Karl R., Saba, Elias S., Kocharyan, Armine, Daher, Ghazal S., Lohse, Christine M., Marinelli, John P., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | March 9, 2022 | Volume: 43 | Issue: 6 | Pages: 604-610

10.1097/mao.0000000000003520 | PMID 35261385 Get It

Objective To characterize the natural history of hearing loss for patients presenting with serviceable hearing (SH) who undergo a wait-and-scan approach for sporadic vestibular schwannoma (VS) using aggregate time-to-event survival analysis. Study Design Systematic review. Setting Published international English literature, January 1, 2000 to May 31, 2020. Patients Patients with sporadic VS entering a wait-and-scan approach with SH at diagnosis. Interventions Observation with serial MRI and audiometry. Results In total, 3,652 patients from 26 studies were included for analysis. Mean age at diagnosis was 58.8 years (SD, 4.1). Mean follow-up was 49.2 months (SD, 26.5). In total, 755 patients (21%) failed conservative treatment and underwent radiosurgery or microsurgery at the time of last follow-up. The average loss to follow-up was 6.9% (SD, 11.1). A total of 1,674 patients had SH at the time of diagnosis. Survival rates for maintaining SH were 96% at 1 year, 77% at 3 years, 62% at 5 years, and 42% at 10 years following diagnosis. Conclusion In this systematic review, aggregate data from 3,652 patients across 26 studies show consistent patterns in progression of hearing loss during observation for patients with sporadic VS as a function of time. As an easy-toremember conservative benchmark for those presenting with SH at diagnosis: approximately 75% retain SH at 3 years, 60% at 5 years, and 40% at 10 years.
Current Estimates of Cochlear Implant Utilization in the United States
Nassiri, Ashley M. , Sorkin, Donna L., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | March 9, 2022 | Volume: 43 | Issue: 5 | Pages: e558-e562

10.1097/mao.0000000000003513 | PMID 35261379 Get It

Objective: To present key data from a private marketing report that characterizes U.S. cochlear implant (CI) utilization, potential CI candidate and recipient population sizes, and CI market growth. Patients: Individuals who may benefit from CI and CI recipients in the United States. Interventions: Cochlear implantation. Main outcome measures: CI utilization, potential CI candidate and recipient population sizes, and CI market size and value. Results: As of 2015, a cumulative 170,252 people (240,056 devices) had undergone cochlear implantation in the United States. In the year 2015, approximately 30% of devices were implanted in bilateral CI patients, through simultaneous or sequential implantation. When considering traditional audiometric CI candidacy criteria (patients with severe to profound sensorineural hearing loss in the better hearing ear), utilization rates among the population who may benefit from CI approximated 12.7%. When considering expanded criteria including individuals with single-sided deafness or asymmetrical hearing loss (severe to profound hearing loss in the worse hearing ear), utilization rates approximated 2.1%. In 2015, there was a net increase of 20,093 individuals who may have benefited from CI who had not undergone CI, adding to the group of about 1.3 M untreated audiometric CI candidates who existed prior to that year. The CI market was valued at $450.8 M in 2015, with an average device selling price of $25,701 per device. Conclusions: CI utilization rates remain low among individuals who meet audiometric criteria for CI. Although the annual proportion of CI recipients to new audiometric candidates has increased, the total population of untreated audiometric CI candidates continues to rise.
SARS‐CoV‐2 vaccination and practical points in psoriasis patients: A narrative review
Hatami, Parvaneh , Aghazadeh, Nessa , Afshar, Zeinab Mohseni , Hatami, Parvaneh , Aghazadeh Mohandesi, Nessa , Aryanian, Zeinab , Balighi, Kamran , Goodarzi, Azadeh

Mayo Clinic

Dermatologic Therapy | March 9, 2022 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/dth.15430 | PMID 35261123 Get It

Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial
Marbach, Jeffrey A., Santo, Pietro Di, Kapur, Navin K. , Thayer, Katherine L. , Simard, Trevor, Jung, Richard G. , Parlow, Simon , Abdel‐Razek, Omar, Labinaz, Marino, Froeschl, Michael, Mathew, Rebecca, Hibbert, Benjamin , Fernando, Shannon M , Hibbert, Benjamin , Marbach, Jeffrey A., Santo, Pietro Di, Kapur, Navin K , Thayer, Katherine L. , Simard, Trevor, Jung, Richard G. , Parlow, Simon , Abdel‐Razek, Omar, Labinaz, Marino, Froeschl, Michael, Mathew, Rebecca

Mayo Clinic

Journal of the American Heart Association | March 9, 2022 | Volume: 11 | Issue: 6 | Pages: No page available

10.1161/jaha.121.023322 | PMID 35261289 Get It

Background Recent studies have shown improved outcomes in cardiogenic shock through protocols directed toward early identification and initiation of mechanical circulatory support. However, objective therapeutic targets—based on clinical and/or laboratory data—to guide real‐time clinical decision making are lacking. Lactate clearance has been suggested as a potential treatment target because of its independent association with mortality. Methods and Results In a post hoc analysis of the DOREMI (Dobutamine Compared to Milrinone in the Treatment of Cardiogenic Shock) trial—a randomized, double‐blind, controlled trial comparing milrinone to dobutamine in the treatment of cardiogenic shock—we used prospectively collected lactate data to evaluate lactate clearance as a surrogate marker for in‐hospital mortality. In total, 82 (57.7%) patients survived to hospital discharge (survivors). In multivariate logistic regression analysis, complete lactate clearance, percentage lactate clearance, and percentage lactate clearance per hour were independently associated with survival beginning as early as 8 hours after enrollment. Complete lactate clearance was the strongest predictor of survival at all time points, with odds ratios ranging between 2.46 (95% CI, 1.09–5.55; P =0.03) at 8 hours to 5.44 (95% CI, 2.14–13.8; P <0.01) at 24 hours. Conclusions Complete lactate clearance is a strong and independent predictor of in‐hospital survival in patients with cardiogenic shock. Together with previously published data, these results further support the validity of lactate clearance as an appropriate surrogate for mortality and as a potential therapeutic target in future cardiogenic shock trials. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03207165.
Lipophagy at a glance
Schott, Micah B. , Rozeveld, Cody N., Weller, Shaun G. , McNiven, Mark A. , Schott, Micah B

Mayo Clinic

Journal of Cell Science | March 9, 2022 | Volume: 135 | Issue: 5 | Pages: No page available

10.1242/jcs.259402 | PMID 35260889 Get It

ABSTRACT Lipophagy is a central cellular process for providing the cell with a readily utilized, high energy source of neutral lipids. Since its discovery over a decade ago, we are just starting to understand the molecular components that drive lipophagy, how it is activated in response to nutrient availability, and its potential as a therapeutic target in disease. In this Cell Science at a Glance article and the accompanying poster, we first provide a brief overview of the different structural and enzymatic proteins that comprise the lipid droplet (LD) proteome and reside within the limiting phospholipid monolayer of this complex organelle. We then highlight key players in the catabolic breakdown of LDs during the functionally linked lipolysis and lipophagy processes. Finally, we discuss what is currently known about macro- and micro-lipophagy based on findings in yeast, mammalian and other model systems, and how impairment of these important functions can lead to disease states.